Eptinezumab is a Monoclonal Antibody owned by H. Lundbeck, and is involved in 30 clinical trials, of which 19 were completed, 9 are ongoing, and 2 are planned.

Eptinezumab is a calcitonin gene-related peptide (CGRP) inhibitory humanized monoclonal antibody. Peripheral release of CGRP from trigeminal nerve fibres within the dura and from trigeminal ganglion neurons might contribute to peripheral sensitization of trigeminal nociceptors. Activation of trigeminal fibers conveys a pain response to the brainstem and from there to higher brain centers. Activation also evokes the release of vasoactive peptides such as substance P and CGRP from trigeminal fibers. These peptides exacerbate vasodilation and cause neurogenic inflammation. These effects are characterized by vasodilation, leakage of blood vessels and degranulation of mast cells. This further increases the activation of the sensory trigeminal fibers and consequent transmission of pain impulses to the brain causing migraine related headache.

The revenue for Eptinezumab is expected to reach a total of $9.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Eptinezumab NPV Report.

Eptinezumab was originated by Lundbeck Seattle BioPharmaceuticals and is currently owned by H. Lundbeck.

Eptinezumab Overview

Eptinezumab (Vyepti) is a humanized immunoglobulin G1(IgG1) monoclonal antibody, which is produced in Pichia pastoris yeast cells by recombinant DNA technology. It is formulated as solution, concentrate solution for intravenous route of administration. Vyepti is indicated as preventive treatment of migraine in adults.

Eptinezumab is under development for the treatment of episodic cluster headache (eCH), chronic migraine and frequent episodic migraine in EU and Canada. It is administered as an intramuscular, intravenous infusion and subcutaneous injection. The drug candidate is a genetically engineered monoclonal antibody acts by targeting calcitonin gene related peptide(CGRP). It is based on Antibody Selection (ABS) process and Mab Xpress antibody production system. The production system exploits yeast expression system to make fully functional whole antibodies.

H. Lundbeck Overview

H. Lundbeck (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of Alzheimer’s disease, migraine, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, France, Italy, and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, Australia, the US, and other countries. Lundbeck is headquartered in Valby, Denmark.

The company reported revenues of (Danish Krone) DKK16,299 million for the fiscal year ended December 2021 (FY2021), a decrease of 7.8% over FY2020. In FY2021, the company’s operating margin was 12.3%, compared to an operating margin of 11.3% in FY2020. In FY2021, the company recorded a net margin of 8.1%, compared to a net margin of 8.9% in FY2020. The company reported revenues of DKK4,719 million for the third quarter ended September 2022, an increase of 5.5% over the previous quarter.

Quick View – Eptinezumab

Report Segments
  • Innovator (NME)
Drug Name
  • Eptinezumab
Administration Pathway
  • Intramuscular
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.